# Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions

> **NCT02091908** · PHASE3 · COMPLETED · sponsor: **Seqirus** · enrollment: 540 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Novartis Investigational H5N1 vaccine
- **BIOLOGICAL:** Novartis Investigational H5N1 vaccine
- **BIOLOGICAL:** Novartis Seasonal Influenza Vaccine
- **BIOLOGICAL:** Novartis Seasonal Influenza Vaccine

## Key facts

- **NCT ID:** NCT02091908
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2016-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091908, "Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02091908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*